BSE Code: | NSE Code: | ISIN: | Sector:
Research Report Detail
|Report Date||Call||Price@Call||Target Price
|Current Status||Time Horizon|
|Bank of America Merrill Lynch
|Closed|| Long (1Y)
Bank of America Merrill Lynch downgrades Sun Pharma
Bank of America Merrill Lynch has downgraded Sun Pharma to neutral from buy for target price of Rs 855/share. It says Taro is facing increasing competition and US growth is likely to moderate from here on. BofAML adds that it prefer Lupin over Sun Pharma.